By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Corixa Corporation 

1900 9th Avenue, Suite 1100

Seattle  Washington  98101  U.S.A.
Phone: 206-366-3700 Fax: 206-366-4700

Corixa is a biopharmaceutical company developing oncology and immunology products that manage human diseases. On June 30, 2003, Corixa announced that the FDA approved BEXXAR for the treatment of patients with CD20 positive,
follicular, NHL, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.

Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. In addition
to BEXXAR, Corixa currently has multiple programs in clinical development, including several product candidates that have advanced to and through late stage clinical trials. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by
Corixa(tm) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, with additional operations in Hamilton, Mont., and South San Francisco. For more information, please visit Corixa's Web site at


  • Steven Gillis, Ph.D., Chairman and Chief Executive Officer
  • Michelle Burris, Senior Vice President and Chief Financial Officer
  • David Fanning, Senior Vice President and Chief Operating Officer

Last Updated: 10-18-04

Key Statistics

Ownership: Public

Web Site: Corixa Corporation
Employees: 400
Symbol: CRXA



Genesis Research and Development Corporation 

Gen-Probe Incorporated (Acquired by Hologic)  In January 2005, Gen-Probe signed an agreement with Corixa to license rights to develop molecular diagnostic tests for approximately 50 potential genetic markers in the areas of prostate, ovarian, cervical, kidney, lung and colon cancer.

GlaxoSmithKline (North Carolina) 

Company News
PanBio Limited (PBO.AX) Purchases Intellectual Property From Corixa Corporation (CRXA) For Detecting Tick Borne Diseases10/19/2005 5:13:16 PM
Corixa Corporation (CRXA) To Present At Lehman Brothers Global Healthcare Conference 10/19/2005 5:13:09 PM
Corixa Corporation (CRXA) To Present At Invest Northwest Life Sciences Conference10/19/2005 5:13:02 PM
Corixa Corporation (CRXA) Announces Fourth Quarter And Year-End 2004 Financial Results10/19/2005 5:13:00 PM
Conference Call/Webcast Alert: Corixa Corporation (CRXA) Fourth Quarter And Year End 2004 Earnings Conference Call10/19/2005 5:12:54 PM
Corixa Corporation (CRXA) And Lorantis Announce Joint Collaboration To Develop Therapeutic Hepatitis B Vaccine10/19/2005 5:12:54 PM
New Era For Biotech?10/19/2005 5:12:40 PM
Corixa Corporation (CRXA) Announces European Approval For Fendrix, GlaxoSmithKline Biologicals' (GSK) Hepatitis B Vaccine Containing Corixa's MPL Adjuvant10/19/2005 5:12:39 PM
Lymphoma Treatment Shows Promise10/19/2005 5:12:37 PM
Genitope Corporation (GTOP) Adds To Operating Management Team10/19/2005 5:12:34 PM